Replimune Group Inc. (REPL)
NASDAQ
Real-time Data
01:30 PM
Day's Range
14.5152 wk Range
1.50Overview - REPL - Replimune Group Inc.
Key Statistics
Valuation
Enterprise Value
1.30B
P/E (Trailing)
‪-4.35‬
P/E (Forward)
‪-8.02‬
PEG Ratio
‪-8.02‬
Price / Book
‪11.74‬
EV / EBITDA
‪-4.50‬
Profitability
Profit Margin
‪0.00%‬
Operating Margin
‪0.00%‬
Return on Assets
‪-51.29%‬
Return on Equity
‪-134.28%‬
Ownership
Shares Outstanding
82.71M
Float
67.61M
Short % of Shares Outstanding
‪57.95%‬
Held by Insiders
‪1.70%‬
Held by Institutions
‪104.19%‬
Price stats
Beta
‪0.90‬
50-Day Avg
‪11.16‬
200-Day Avg
‪8.26‬
Dividends
Payout Ratio
‪0.00%‬
Analyst Consensus
8 analysts
Average price target
‪$ 19.33‬Shariah Compliance
Report Date: Feb 18, 2025
Screened by Zoya using the AAOIFI methodology.
Market Cap - REPL - Replimune Group Inc.
Peers - REPL - Replimune Group Inc.
Peer Comparison
Compared with companies in Biotechnology listed on NASDAQ.
- REPLNASDAQReplimune Group Inc.1.38BMarket Cap+62.68%52-week change-4.35P/E (Trailing)‪0.00%‬Profit Margin
- ARGXNASDAQargenx SE American Depositary Receipt62.93BMarket Cap+33.08%52-week change39.69P/E (Trailing)‪32.26%‬Profit Margin
- ALNYNASDAQAlnylam Pharmaceuticals Inc31.58BMarket Cap-87.93%52-week change40.23P/E (Trailing)‪16.12%‬Profit Margin
- BNTXNASDAQBioNTech SE28.34BMarket Cap+7.12%52-week change160.80P/E (Trailing)‪-63.63%‬Profit Margin
- ASNDNASDAQAscendis Pharma A/S16.52BMarket Cap+21.81%52-week change19.30P/E (Trailing)‪70.84%‬Profit Margin
- BBIONASDAQBridgeBio Pharma, Inc.15.84BMarket Cap+39.72%52-week change-21.44P/E (Trailing)‪-97.02%‬Profit Margin
- BMRNNASDAQBiomarin Pharmaceutical Inc.12.59BMarket Cap+11.71%52-week change180.27P/E (Trailing)‪2.14%‬Profit Margin
Profile Summary - REPL - Replimune Group Inc.
About
Replimune Group Inc. is a clinical-stage biotechnology company dedicated to developing and commercializing oncolytic immunotherapies for cancer treatment. Its proprietary product candidates harness oncolytic viruses to selectively replicate in and destroy tumor cells while activating the patient's immune system…
The information on this page is provided for general informational purposes only and is not investment advice.
Market data provided by Twelve Data. Shariah compliance data provided by Zoya. Charting by TradingView.
Last updated:
